Worsening of soft tissue dystrophic calcification in an osteoporotic patient treated with teriparatide.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 29247298.
- Also identified by DOI 10.1007/s00198-017-4330-7.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Teriparatide, used for treatment of osteoporosis in patients at high risk of fracture risk, sometimes results in mild and transient hypercalcemia. There have been two recent reports of worsening dystrophic calcification in patients with autoimmune disorders following teriparatide treatment. We report a patient with severe osteoporosis and without a pre-existing autoimmune disorder, who developed symptomatic worsening of dystrophic calcification 4 months after teriparatide was initiated. Symptoms resolved within 1 week of teriparatide cessation.
Medical subject headings
- Bone Density Conservation Agents
- Calcinosis
- Connective Tissue Diseases
- Osteoporosis
- Teriparatide